FDA Medical Device Classifications

Every medical device sold in the United States — from tongue depressors to MRI scanners to artificial hearts — sits inside an FDA classification framework that determines how the manufacturer can bring it to market, what controls apply during commercial distribution, and what happens when something goes wrong. The framework was created by the Medical Device Amendments of 1976 to the Federal Food, Drug, and Cosmetic Act, and is implemented through 16 body-system Parts under Title 21 CFR that organize roughly 1,700 generic device types by body system — clinical chemistry (Part 862), hematology (Part 864), immunology (Part 866), pathology and microbiology (Parts 864, 866), anesthesiology (Part 868), cardiovascular (Part 870), dental (Part 872), ear/nose/throat (Part 874), gastroenterology and urology (Part 876), general and plastic surgery (Part 878), general hospital (Part 880), neurological (Part 882), obstetrical and gynecological (Part 884), ophthalmic (Part 886), orthopedic (Part 888), physical medicine (Part 890), and radiology (Part 892).

Legal Authority

• 21 U.S.C. § 360c — Federal Food, Drug, and Cosmetic Act § 513: establishes the three-class risk-based medical device classification system; requires classification panels to classify all medical devices into Class I (general controls), Class II (special controls), or Class III (premarket approval)
• 21 U.S.C. § 360e — FDCA § 515: requires premarket approval (PMA) for Class III devices; PMAs require demonstration of safety and effectiveness through valid scientific evidence including clinical data
• 21 U.S.C. § 360k — FDCA § 510(k): establishes the substantial equivalence pathway allowing Class II devices to be cleared by demonstrating equivalence to a legally marketed predicate device

Key Mechanics

The three-tier classification system determines what kind of FDA review a device needs before marketing. Class I devices (about 47% of all devices) are low-risk (bandages, tongue depressors, non-powered wheelchairs) — most are exempt from premarket notification and are subject only to general controls (registration, good manufacturing practice, labeling). Class II devices (about 43%) are moderate risk — most require 510(k) clearance, demonstrating substantial equivalence to a predicate device already on the market; FDA does not perform independent clinical review of most 510(k) submissions. Class III devices (about 10%) are high-risk or novel life-sustaining devices — they must go through PMA, which requires clinical trial data demonstrating safety and effectiveness. FDA classifies new device types through the de novo pathway when no predicate exists and the device presents moderate risk.

Current Rule (2026)

How Classification Works

FDA divides every device into one of three classes based on the level of regulatory control needed to provide reasonable assurance of safety and effectiveness:

• Class I — General controls only. The lowest-risk devices: bandages, manual stethoscopes, elastic bandages, tongue depressors. General controls (registration, listing, labeling, good manufacturing practice) are enough. Most Class I devices are exempt from premarket notification — manufacturers can start marketing without filing a 510(k), provided they comply with the general controls and don't exceed the limitations in the "exemption" provision of each Part (typically § XXX.9 within each device classification Part).
• Class II — General controls + special controls. Moderate-risk devices: infusion pumps, electric wheelchairs, surgical drapes, contact lenses, most in-vitro diagnostic tests. Special controls layer in performance standards, special labeling requirements, FDA guidance documents, mandatory postmarket surveillance, or premarket data requirements. Most Class II devices require 510(k) premarket notification — the manufacturer must demonstrate that the device is "substantially equivalent" to a legally marketed predicate device. About 90% of new device clearances flow through the 510(k) pathway.
• Class III — Premarket approval required. The highest-risk devices: pacemakers, heart valves, implanted defibrillators, hip implants made of new materials, breast implants, devices for sustaining life or supporting human life. Class III devices must obtain a Premarket Approval (PMA) under 21 U.S.C. § 360e — a far more rigorous process requiring substantial clinical data demonstrating safety and effectiveness. PMAs are device-specific and approve only the exact product covered by the submission; significant changes require a supplement.

The classification of a specific generic device type is set forth in the body-system Part. For example, 21 CFR 862.1020 classifies acid phosphatase test systems as Class II (special controls), exempt from 510(k) subject to the limitations in § 862.9; 21 CFR 870.3610 classifies implantable pacemaker pulse generators as Class III, requiring PMA; 21 CFR 880.2400 classifies bed-side rails as Class I, exempt from 510(k).

The 16 Body-System Parts

Each Part has the same internal structure: a general-provisions subpart (scope, definitions, the § X.9 exemption limitations), followed by topic subparts grouping similar devices, and each device gets its own section with an Identification paragraph (what the device is) and a Classification paragraph (Class I/II/III + 510(k) status + applicable special controls).

• Part 862 — Clinical chemistry and clinical toxicology (259 sections): blood gas analyzers, glucose meters, electrolyte test systems, lipid panels, drug-of-abuse test kits, therapeutic drug monitoring assays, automated clinical chemistry analyzers
• Part 864 — Hematology and pathology (124 sections): complete blood count analyzers, flow cytometers, blood collection tubes, automated cell counters, hemoglobin test systems, coagulation analyzers, tissue processors
• Part 866 — Immunology and microbiology (252 sections): antinuclear antibody test systems, HIV test kits, COVID-19 diagnostic test kits, microbial identification systems, antimicrobial susceptibility test systems, pregnancy test kits, hepatitis test kits
• Part 868 — Anesthesiology (150 sections): anesthesia gas machines, breathing circuits, pulse oximeters, capnographs, anesthesia ventilators, laryngoscopes, oxygen masks, vaporizers
• Part 870 — Cardiovascular (167 sections): pacemakers, implantable defibrillators, cardiac catheters, blood pressure monitors, ECG electrodes, prosthetic heart valves, coronary stents, balloon catheters, cardiac monitors
• Part 872 — Dental (140 sections): dental drills, orthodontic brackets, dental implants, dental cements, dental X-ray systems, dental amalgam, root canal instruments, intraoral cameras
• Part 874 — Ear, nose, and throat (54 sections): hearing aids, audiometers, cochlear implants, tympanostomy tubes, nasal endoscopes, surgical lasers for ENT, tonsillectomy instruments
• Part 876 — Gastroenterology and urology (101 sections): endoscopes, urinary catheters, dialysis machines, peritoneal dialysis systems, urodynamic measurement systems, prostate biopsy instruments, hemorrhoid ligation devices
• Part 878 — General and plastic surgery (106 sections): surgical staplers, sutures, electrosurgical units, surgical drapes, scalpels, retractors, breast implants, surgical lasers, hyperbaric chambers
• Part 880 — General hospital and personal use (118 sections): infusion pumps, infant warmers, IV administration sets, hospital beds, patient lifts, bed-side rails, gowns and drapes, sphygmomanometers, examination gloves, syringes
• Part 882 — Neurological (140 sections): EEG electrodes, neurostimulators (including spinal cord and vagus nerve stimulators), shunts, intracranial pressure monitors, neurological lasers, cranial drills, biofeedback equipment
• Part 884 — Obstetrical and gynecological (104 sections): IUDs, fetal monitors, ultrasonic fetal heart detectors, contraceptive diaphragms, hysteroscopes, vaginal speculums, breast pumps, in vitro fertilization equipment
• Part 886 — Ophthalmic (143 sections): contact lenses, intraocular lenses, ophthalmoscopes, tonometers, slit lamps, retinoscopes, surgical lasers for the eye, eye charts, soft contact lens care products
• Part 888 — Orthopedic (105 sections): hip prostheses, knee prostheses, bone screws/plates/nails, spinal fusion devices, orthopedic surgical instruments, bone cement, prosthetic limb components
• Part 890 — Physical medicine (91 sections): therapeutic massagers, TENS units, ultrasound therapy devices, hot/cold packs, exercise equipment for therapy, walkers, canes, prosthetic limbs
• Part 892 — Radiology (90 sections): X-ray systems, CT scanners, MRI scanners, ultrasound imaging systems, mammography systems, nuclear medicine cameras, radiation therapy systems, fluoroscopic systems

The 510(k) Substantial Equivalence Pathway

Most new devices (Class II, and some Class III devices that pre-date 1976) come to market through the 510(k) premarket notification process. The manufacturer submits a document to FDA at least 90 days before commercial distribution showing that the new device is substantially equivalent to a legally marketed predicate device — meaning it has the same intended use and either the same technological characteristics or different technological characteristics that don't raise different questions of safety and effectiveness.

The 510(k) process compresses the regulatory burden enormously compared to a PMA: instead of demonstrating safety and effectiveness from scratch with clinical trials, the manufacturer leverages the predicate's prior clearance. This is also why innovative devices that have no predicate cannot use 510(k) and must instead go through De Novo classification (a relatively newer pathway that creates a new Class I or Class II classification for novel devices) or PMA.

Common predicates create classification "device families" — once one company gets a glucose meter cleared, subsequent glucose meter manufacturers reference that predicate. The 510(k) framework is sometimes criticized for "predicate creep" — over decades, devices can drift considerably from the original 1976 predicate through a chain of "substantially equivalent" clearances, with no formal review of whether the chain still makes sense.

The PMA Pathway

For Class III devices, FDA requires Premarket Approval — the most rigorous device pathway. PMA submissions typically require:

• Comprehensive manufacturing controls documentation
• Bench testing demonstrating performance characteristics
• Animal studies for implants or surgical devices
• One or more pivotal clinical trials in humans, typically randomized and blinded where feasible
• A complete risk/benefit analysis
• Proposed labeling and physician training requirements

PMA review typically takes 12–18 months and includes advisory committee review for novel devices. Approval is device-specific — any meaningful change (different materials, new indication, modified labeling) requires a PMA Supplement, which itself can take months to years. The PMA process is closer in burden to the new drug approval (NDA) pathway than to 510(k).

Special Controls

For Class II devices, special controls are FDA's mechanism to add device-specific or risk-specific requirements that go beyond the general controls applicable to all devices. Special controls can include:

• Performance standards (mandatory test methods and acceptance criteria — e.g., maximum acceptable shock hazard for an electrocardiograph)
• Patient and physician labeling requirements (specific contraindications, warnings, instructions for use)
• FDA-recognized consensus standards that the device must conform to (e.g., ISO 10993 for biocompatibility)
• Mandatory premarket clinical data for certain device categories
• Postmarket surveillance requirements (Section 522 orders)
• Tracking of high-risk implants under 21 U.S.C. § 360i(e)

Special controls are codified in FDA guidance documents specific to each device type, available at https://www.fda.gov/medical-devices/.

How It Affects You

If you use medical devices (most people do — glucose meters, contact lenses, sleep apnea machines, surgical implants, dental work): every one of these has a classification under 21 CFR 862–892 that determined what evidence the manufacturer had to provide before bringing it to market. Class I devices like bandages or examination gloves come to market with effectively no premarket review — FDA trusts general controls (registration, labeling, GMP) to provide reasonable assurance of safety. Class II devices like infusion pumps or hearing aids went through a 510(k) clearance that demonstrated substantial equivalence to an earlier device. Class III devices like pacemakers or coronary stents went through full PMA review with clinical trials before approval. If a device is recalled or has a safety problem, FDA's recall classification (Class I/II/III recalls, distinct from device classifications) and the device adverse event reporting system are how that information reaches you — check the FDA medical device safety database (MAUDE) for any device you depend on.

If you're a device manufacturer or developer: classification determines your regulatory pathway and timeline. A Class I exempt device can be on the market in weeks (registration, listing, labeling). A Class II 510(k) device typically takes 3–9 months from submission to clearance, plus the time to do bench testing and prepare the submission. A Class III PMA device typically takes 3–7 years from initial concept to approval, including clinical trials. For genuinely novel devices, the De Novo classification request lets you avoid forcing your device into an inappropriate PMA — if no predicate exists but the risk profile is low/moderate, De Novo creates a new Class I or II classification with appropriate special controls. The 21st Century Cures Act (2016) and the FDA Modernization Act of 1997 expanded the De Novo pathway substantially.

If you're a clinician prescribing or using devices: the device class affects what evidence you can find about it. Class III devices have public PMA summaries with clinical data; Class II devices have publicly available 510(k) summaries that often only reference the predicate without independent clinical data; Class I devices have minimal publicly available premarket data beyond manufacturer labeling. The FDA's 510(k) database and PMA database let you look up any device by manufacturer or generic name. For implants and life-supporting devices, ask whether the device is currently subject to a tracking requirement under FDA's mandatory tracking system — that affects long-term follow-up obligations.

State Variations

• Device regulation is federally preempted for any device that has received PMA approval — states may not impose additional safety or effectiveness requirements (Riegel v. Medtronic, 552 U.S. 312 (2008)). This is the strongest preemption in food and drug law and is a major reason device manufacturers prefer PMA over 510(k) where the choice is available.
• For 510(k)-cleared devices, preemption is narrower — state common-law claims based on requirements that "parallel" federal requirements can proceed (Medtronic v. Lohr, 518 U.S. 470 (1996)).
• States retain authority over the practice of medicine, so state medical boards regulate how clinicians use FDA-cleared devices (including off-label use), even though they cannot regulate the devices themselves.
• States regulate medical device sales tax, retail licensing of certain devices (hearing aids, contact lenses), and the practice of fitting devices (audiologists, optometrists).

Statutory Authority

This regulatory regime implements:

• 21 U.S.C. § 360c — Classification of devices intended for human use (the statutory basis for the I/II/III framework)
• 21 U.S.C. § 360e — Premarket approval (PMA pathway)
• 21 U.S.C. § 360(k) — Premarket notification (510(k) pathway)
• 21 U.S.C. § 360c(f)(2) — De Novo classification
• 21 U.S.C. § 351 — Adulteration (the basis for FDA's authority to require general controls and special controls)
• 21 U.S.C. § 360i — Records, reports, and notifications (MDR adverse event reporting, tracking)

Recent Rulemakings

• December 2019 (84 FR 71796–71797) — FDA reclassified several immunology and clinical chemistry devices in 21 CFR 866 and 862 from Class III to Class II with special controls, recognizing that decades of experience and consensus standards made full PMA review unnecessary for those specific device types.
• April 2020 onward — Emergency Use Authorizations during COVID-19 created a parallel pathway for diagnostic devices outside the standard 862/866 classification process. EUAs have since been transitioned (or in some cases withdrawn) as the public-health emergency ended; FDA has issued guidance on transitioning EUA devices to formal clearance pathways.
• 2017 (82 FR 38712) — De Novo final rule formalized the application procedures and timelines for novel devices seeking new classification.

Pending Action

Related Pages

• FDA Medical Devices — the overall FDA device regulatory framework including UDI, recalls, and adverse-event reporting
• FDA Drug Approval — the parallel NDA/ANDA framework for drugs (contrast with PMA/510(k) for devices)
• FDA Blood and Biologics Standards — biological products with overlapping but distinct device pathways
• Biosimilars (BPCIA) — combination products and biologic-device combinations
• FDA Food and Drug Administration — the agency's full regulatory portfolio